SEVERE OSTEOPOROSIS · OSTEOPOROTIC FRACTURES · LOW BONE MINERAL DENSITY
A physician-led, laboratory-verified treatment programme targeting bone mineral density loss, fracture risk and impaired bone remodelling — tailored to the individual biology, hormonal profile and clinical stage of each osteoporosis patient.
Request Medical ConsultationAbout the Condition
Severe osteoporosis is a systemic skeletal disorder characterised by critically low bone mineral density (BMD), deterioration of bone microarchitecture and a markedly elevated risk of fragility fractures — particularly of the vertebrae, hip and wrist.
The condition reflects a sustained imbalance between bone formation (osteoblast activity) and bone resorption (osteoclast activity), compounded by progressive exhaustion of the mesenchymal stem cell pool responsible for generating new bone-forming cells. As bone tissue loses structural integrity, even minimal trauma or routine daily activity can result in fracture.
Standard pharmacological management — bisphosphonates, denosumab, teriparatide — can slow resorption or stimulate formation, but does not address the underlying cellular exhaustion driving progressive bone loss. Our programme targets these biological mechanisms directly.
Postmenopausal Osteoporosis (Type I)
The most prevalent form, driven by oestrogen decline following menopause. Rapid trabecular bone loss occurs in the first 5–10 years post-menopause, disproportionately affecting vertebral bodies and distal radius. Accounts for the majority of vertebral compression fractures in women aged 55–75.
Age-related Osteoporosis (Type II)
Affects both cortical and trabecular bone in men and women over 70. Driven by age-related decline in osteoblast function, reduced calcium absorption, vitamin D insufficiency and progressive mesenchymal stem cell depletion. Hip fractures are the hallmark complication.
Steroid-induced Osteoporosis
The most common form of secondary osteoporosis. Prolonged glucocorticoid use suppresses osteoblast differentiation, accelerates osteocyte apoptosis and increases osteoclast lifespan. Bone loss can be rapid — clinically significant within 3–6 months of continuous corticosteroid therapy.
Secondary Osteoporosis
Caused by underlying endocrine disorders (hyperparathyroidism, hyperthyroidism, hypogonadism), chronic medication use (anticonvulsants, aromatase inhibitors, proton pump inhibitors), malabsorption syndromes or prolonged immobilisation. Requires identification and management of the primary cause alongside bone-targeted intervention.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, bone density status, fracture history, hormonal profile and overall clinical condition.
We do not offer a cure for osteoporosis. Our programme is designed to target the biological mechanisms driving bone loss — with the clinical objective of improving bone mineral density markers, reducing fracture risk and restoring functional confidence.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
20
severe osteoporosis patients treated
68%
demonstrated measurable improvement in bone density markers within 6–12 months
55%
showed clinically meaningful DEXA T-score improvement at 12-month follow-up
72%
reported reduced fracture-related anxiety and improved mobility confidence
↓ 38%
average reduction in bone turnover marker CTX, indicating decreased bone resorption
60%
maintained sustained bone density stabilisation — follow-up to 2 years
Improved DEXA T-score or stabilisation of bone density decline
68%
Reduction in bone resorption markers (CTX)
62%
Increase in bone formation markers (P1NP)
55%
Reduced pain and improved weight-bearing capacity
64%
Improved postural stability and fall-risk confidence
58%
3–8 weeks
Initial biological response
3–6 months
Clinically meaningful change in bone turnover markers
6–18 months under continued monitoring
Bone remodelling and structural adaptation
Important: Outcomes depend on osteoporosis subtype, baseline DEXA T-score, fracture history, hormonal status and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“After my third vertebral fracture I was genuinely afraid to move. Bisphosphonates had done very little over four years. After the programme, my follow-up scan showed real improvement for the first time. My endocrinologist called it unusual for someone my age. I walk every day now, without the cane.”
Patient
Postmenopausal osteoporosis (Type I) · Japan
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our osteoporosis programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's bone density status, hormonal profile, fracture history and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection — not surgical instruments. No implants, no hardware, no operative risk.
No general anaesthesia
Particularly relevant for elderly osteoporosis patients where anaesthesia carries elevated cardiovascular and cognitive risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the underlying biology, not just bone turnover rates
Rather than solely inhibiting resorption or artificially stimulating formation, our protocol addresses mesenchymal stem cell depletion, chronic inflammation and impaired osteoblast function — the biological drivers of progressive bone loss.
Complements existing medication
Our programme is compatible with bisphosphonates, denosumab, teriparatide and other current standard medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For elderly patients where long-distance travel is difficult, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent progenitor cells capable of differentiating into osteoblasts — the cells responsible for new bone formation. In severe osteoporosis, the endogenous MSC pool is depleted, and the remaining cells show reduced osteogenic differentiation capacity. Replenishing this pool is central to restoring the bone formation side of the remodelling equation.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are then expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Severe Osteoporosis
In osteoporosis, the fundamental problem is that bone-forming cells cannot keep pace with bone-resorbing cells. MSCs directly address the supply side of this equation — providing fresh osteogenic progenitors that can differentiate into osteoblasts and contribute to new bone matrix deposition where it is most needed.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, bone density status, fracture history, hormonal profile and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current DEXA results, fracture history, medication regimen and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — including DEXA scans, bone turnover markers (P1NP, CTX), hormonal panels and imaging. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme.
Structured physiotherapy and weight-bearing exercise sessions with our specialist, adapted to your current bone density status and functional capacity. Fall-prevention training and postural stability work are integrated into every programme.
Your dedicated coordinator monitors bone density progression, reviews follow-up DEXA scans and bone turnover markers, and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of osteoporosis patients, including elderly individuals.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active biological engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including new fracture, acute illness or medication adjustment — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Uncontrolled hyperparathyroidism or other untreated endocrine disorders causing secondary osteoporosis
Post-Treatment
Dedicated rehabilitation specialist
monitors bone density progression, functional capacity and fall-risk status
Personalised weight-bearing exercise programme
adapted to current bone density and fracture risk profile
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, DEXA and bone marker review scheduling, and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Bone remodelling operates on a longer biological timeline than soft tissue repair. Measurable changes in bone density typically require months of sustained cellular activity. The post-treatment period — including structured loading, nutritional optimisation and clinical monitoring — is integral to the therapeutic outcome.
Get Started
If you or someone you love has been diagnosed with severe osteoporosis, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, DEXA results and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
